N/A
Completed N=104
Posterior Capsule Opacification (PCO) Evaluation of the AcrySof SN60AT Lens vs. SN60WF Lens
Source: ClinicalTrials.gov NCT00762021 ↗Enrolled (actual)
104
Serious AEs
0.0%
Results posted
Dec 2010
Primary outcomePrimary: Posterior Capsule Opacification (PCO) — 11.58; 14.04 Percentage of PCO
Summary
To assess posterior capsule opacification (PCO) in patients implanted with either the AcrySof SN60AT lens or the AcrySof SN60WF lens.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Posterior Capsule Opacification (PCO) |
11.58; 14.04 | — |
| PRIMARY 100% LogMAR Best Corrected Visual Acuity (BCVA) |
0.04; 0.07 | — |
| PRIMARY 9% LogMAR Best Corrected Visual Acuity (BCVA) |
0.42; 0.45 | — |
Eligibility Criteria
Inclusion Criteria
- patients with bilateral senile cataracts
- Age > 50 years
- Fit for hospital follow ups
- Pupils dilating > 6mm preoperatively
- Eyes expected to see 6/12 or better postoperatively
Exclusion Criteria
- Diabetes
- On treatment for glaucoma
- Other ocular pathology
- Previous ocular surgery
Data sourced from ClinicalTrials.gov (NCT00762021). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.